Checkpoint Therapeutics Inc (NASDAQ: CKPT) on Monday, plunged -5.60% from the previous trading day, before settling in for the closing price of $3.75. Within the past 52 weeks, CKPT’s price has moved between $1.38 and $4.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -47.67% annually for the last half of the decade. The company achieved an average annual earnings per share of 72.24%. With a float of $38.39 million, this company’s outstanding shares have now reached $45.10 million.
In an organization with 23 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -45168.08%, operating margin of -79817.02%, and the pretax margin is -98868.09%.
Checkpoint Therapeutics Inc (CKPT) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Checkpoint Therapeutics Inc is 21.38%, while institutional ownership is 15.76%. The most recent insider transaction that took place on Dec 18 ’24, was worth 2,330,386. In this transaction CEO, President and Director of this company sold 602,167 shares at a rate of $3.87, taking the stock ownership to the 3,414,813 shares. Before that another transaction happened on Dec 19 ’24, when Company’s CEO, President and Director sold 220,230 for $3.38, making the entire transaction worth $744,377. This insider now owns 3,194,583 shares in total.
Checkpoint Therapeutics Inc (CKPT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 72.24% per share during the next fiscal year.
Checkpoint Therapeutics Inc (NASDAQ: CKPT) Trading Performance Indicators
Checkpoint Therapeutics Inc (CKPT) is currently performing well based on its current performance indicators. A quick ratio of 0.29 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3457.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.44, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.32 in one year’s time.
Technical Analysis of Checkpoint Therapeutics Inc (CKPT)
Let’s dig in a bit further. During the last 5-days, its volume was 3.29 million. That was better than the volume of 0.68 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 39.27%. Additionally, its Average True Range was 0.41.
During the past 100 days, Checkpoint Therapeutics Inc’s (CKPT) raw stochastic average was set at 60.66%, which indicates a significant increase from 38.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 85.49% in the past 14 days, which was higher than the 66.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.58, while its 200-day Moving Average is $2.44. However, in the short run, Checkpoint Therapeutics Inc’s stock first resistance to watch stands at $3.71. Second resistance stands at $3.88. The third major resistance level sits at $4.06. If the price goes on to break the first support level at $3.36, it is likely to go to the next support level at $3.18. The third support level lies at $3.01 if the price breaches the second support level.
Checkpoint Therapeutics Inc (NASDAQ: CKPT) Key Stats
Market capitalization of the company is 172.87 million based on 48,833K outstanding shares. Right now, sales total 100 K and income totals -51,850 K. The company made 40 K in profit during its latest quarter, and -6,670 K in sales during its previous quarter.
